| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
With over 150 years of advanced medical knowledge, our multidisciplinary approach and award-winning team of nephrology experts, pathologists, and laboratory scientists provides the highest standards for renal laboratory care. We believe laboratory medicine offers more than a test result — it is about collaboration to reach actionable answers for patients. Currently, Mayo Clinic physicians are actively enrolling in clinical trials to make patient needs central to the care journey.
“Artificial intelligence will definitely have a huge impact on the clinical and anatomical sides of laboratory medicinE. There are so many applications, and we’re just scratching the surface now.”
Paul Jannetto, Ph.D., director of the Metals Laboratory
OUR DIFFERENCE
The latest
Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.
Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.
Mayo Clinic researchers are tracking the familiar characteristics of kidney stone formers in an online prediction tool that could help sufferers anticipate if they'll experience future episodes.
This week’s Research Roundup highlights the evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
This week’s Research Roundup highlights predicting renal function outcomes after partial and radical nephrectomy.
This week’s Research Roundup highlights the clinical and pathology findings associated consistently with larger glomerular volume.
There have been concerns in the U.S. recently about the possible harmful side effects from absorbing gadolinium-based contrast agents into the body during some MRI exams. To address some of the anxiety and concerns over this issue, Paul Jannetto, Ph.D., DABCC, FAACC, and Joshua Bornhorst, Ph.D., DABCC, FAACC, Co-Directors of the Mayo Clinic Metals Laboratory and leading experts in this field, have compiled the following list of the most up-to-date information.
The National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory societies have announced a new collaboration to remove barriers to testing for chronic kidney disease.
This week’s Research Roundup highlights how the DnaJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN.
A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four years of diagnosis.
This week’s Research Roundup highlights noninvasive assessment of renal fibrosis with magnetization transfer MR imaging.